Holen Sie sich die Stockscreener-App
3.295
0.62%
0.005
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Here’s What Citi Thinks About Larimar Therapeutics (LRMR) - Yahoo Finance
H.C. Wainwright initiates Larimar stock coverage with buy rating - Investing.com UK
LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Larimar stock coverage with buy rating By Investing.com - Investing.com South Africa
Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Larimar Therapeutics Up Nearly 32%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk - Moomoo
Baird Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $5 - Moomoo
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's AtaxiaSlideshow (NASDAQ:LRMR) 2026-07-01 - Seeking Alpha
Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Moomoo
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
LRMR Maintains by Baird -- Price Target Lowered to $5.00 - GuruFocus
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $5 to $25 - Moomoo
Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks (NASDAQ:LRMR) - Seeking Alpha
Larimar Therapeutics submits rolling BLA for nomlabofusp - The Pharma Letter
Buy Recommendation for Larimar Therapeutics (LRMR) Following Mar - GuruFocus
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2500 Growth Benchmark - marketscreener.com
Larimar Therapeutics (LRMR) Faces Stock Decline After Safety Fin - GuruFocus
LRMR Stock Dips As Traders Weigh Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia - grafa.com
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Benzinga
LRMR Stock Slides As Traders Eye Cash Runway And Volatility - StocksToTrade
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) - Yahoo Finance
Larimar submits first module of rolling BLA for nomlabofusp - Investing.com UK
LRMR Stock Holds Support As Biotech Traders Watch Cash Runway - timothysykes.com
Why is Larimar Therapeutics stock sliding today? By Investing.com - Investing.com India
Why is Larimar Therapeutics stock sliding today? - Investing.com
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Larimar Therapeutics stock tumbles after clinical data release By Investing.com - Investing.com Nigeria
Larimar Therapeutics stock tumbles after clinical data release - Investing.com
Larimar Therapeutics Submits First Module of Rolling Bla and Reports Positive Open Label Data for Nomlabofusp in Friedreich?S Ataxia - marketscreener.com
Larimar Therapeutics (LRMR) Submits First Module for Accelerated Approval - GuruFocus
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval - TipRanks
Larimar submits first module of rolling BLA for nomlabofusp By Investing.com - Investing.com South Africa
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark - marketscreener.com
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and strong regulatory progress - TradingView
Larimar Therapeutics submits first module of rolling BLA after positive nomlabofusp open‑label data - TradingView
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approval - TradingView
Larimar says FDA can review nomlabofusp for accelerated approval - Stock Titan
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000E Growth Benchmark - marketscreener.com
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell 3000 Value Benchmark - marketscreener.com
Larimar Therapeutics, Inc. (LRMR) Investigation: Bronstein, Gewir - The National Law Review
Larimar Therapeutics to host investor event on Monday By Investing.com - Investing.com South Africa
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia - The Manila Times
Larimar to discuss Friedreich’s ataxia drug data June 29 - Stock Titan
Larimar Therapeutics, Inc. Actuals & Estimates (NASDAQ:LRMR) - TradingView
LRMR Forecast — Price Target — Prediction for 2027 - TradingView
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
Larimar Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Investor ConfidenceOperating Margin Analysis - dars.gov.et
1.16%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):